Since IL-6 blocking agents are increasingly used to retard progress of inflammatory autoimmune diseases such as rheumatoid arthritis (RA), juvenile idiopathic arthritis, and Castleman’s disease, the amount of clinical information on their effects in patients with autoimmune renal disorders is continuously growing (101, 102). This evidence concerns the gene IL6 and rheumatoid arthritis.